Form 4: Amylyx Pharmaceuticals Co-CEO Joshua Cohen Sells Shares to Cover Tax Obligations

Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, sold shares of common stock on September 30, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On September 30, 2024, Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, sold 18,589 shares of common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $3.1962, with individual transactions ranging from $3.12 to $3.24.
• Following the transaction, Cohen directly owns 3,220,569 shares of Amylyx Pharmaceuticals.
• The sale was automatic and not at the discretion of the reporting person.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing indicates a routine transaction to cover tax obligations, which is neither particularly positive nor negative.

Management Comments

• The sales were automatic and not at the discretion of the Reporting Person.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. This transaction is related to tax obligations and may not reflect a change in the executive's long-term outlook for the company.

Stakeholder Impact

• The sale of shares by a company executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact as it was to cover tax obligations.

Key Dates